Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2973810 | 0.89 | MAPT (0.40) | CYP3A4MAPTBLMPMP22HCAR3 | |
| SCHEMBL13338194 | 0.85 | HCAR3 (0.45) | CYP3A4MAPTBLMPMP22HCAR3 | |
| SCHEMBL2970711 | 0.84 | MAPT (0.37) | CYP3A4MAPTBLMPMP22HCAR3 | |
| SCHEMBL2975715 | 0.84 | MAPT (0.37) | CYP3A4MAPTBLMPMP22HCAR3 | |
| SCHEMBL2966410 | 0.84 | MAPT (0.39) | CYP3A4MAPTBLMPMP22HCAR3 | |
| SCHEMBL2969402 | 0.79 | HCAR3 (0.43) | HCAR3THRBKDM4EALDH1A1 | |
| SCHEMBL4080977 | 0.79 | CYP3A4 (0.31) | CYP3A4MAPTBLMPMP22 | |
| SCHEMBL2966761 | 0.78 | VCAM1 (0.43) | MAPTHCAR3THRBKDM4EALDH1A1 | |
| SCHEMBL13202995 | 0.74 | CYP3A4 (0.33) | CYP3A4MAPTBLMPMP22 | |
| SCHEMBL2977036 | 0.73 | NPC1 (0.40) | CYP3A4HCAR3THRBKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090130020-A1 | DIAGNOSTIC AGENTS FOR POSITRON EMISSION IMAGING USING F-18 RADIO-LABELED AMINO-ALCOHOLS | BAYER SCHERING PHARMA AG (DE) | 2009-05-21 | — | — | US | disclosed |
| WO-2009033584-A2 | DIAGNOSTIC AGENTS FOR POSITRON EMISSION IMAGING USING F-18 RADIO-LABELED AMINO-ALCOHOLS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-03-19 | — | — | WO | disclosed |
| EP-2036578-A1 | Diagnostic agents for positron emission imaging using F-18 radio labeled amino-alcohols | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090130020-A1 | DIAGNOSTIC AGENTS FOR POSITRON EMISSION IMAGING USING F-18 RADIO-LABELED AMINO-ALCOHOLS | ADH1A, ADH5, FABP1 | CYP3A4 3880/4885MAPT 832/4885BLM 2773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.